Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just printed a $7.35, so let see what happens next..
dougheuring, thanks for posting....
gdollasign, be amazed...
I think I'll treat Ariad as an, "old fashion" stock. I'll wait until I see the picture of the Harv on the cover page of Business Week, then I'll sell it all...(snicker)
Ok, read: Ariad Pharmaceuticals : Rida Co-Promote...a Free Head Start on Ponatinib's Future
As others have suggested here, it's kind of a finger in Merck's eye.. Merck is going to partly help fund Ariad's Ponatinib sales force.. I'm sure they do want it stated that way..
The finger was just stuck in the eye:
News for 'ARIA' - (ARIAD PHARMACEUTICALS INC EPS Estimated At -0.62)
Mar 22, 2011 (Nelson's Broker Summaries via COMTEX) --
Company: ARIAD PHARMACEUTICALS INC
Report Headline: "Ariad Pharmaceuticals : Rida Co-Promote...a Free Head Start on Ponatinib's Future"Report Date: March 17, 2011
Current FY EPS Estimate [FY2011]: -0.62
Previous EPS Estimate for Current FY [FY2011]: -0.62
Current Quarter EPS Estimate [Q1]: -0.13
Next FY EPS Estimate [FY2012]: -0.46
Previous EPS Estimate for Next FY [FY2012]: -0.46
Current Recommendation: OVERWEIGHT
Research Firm: joh
Analyst: CORY KASIMOV
Industry: HEALTH/BIOTECH
Au-530,it's obviously hypothetical.. there is no answer..
They're going to keep this ranged bound for another six months?
Harvey talks to the media today on the Merck deal to co-promote:
http://seekingalpha.com/news-article/779009-ariad-exercises-co-promotion-rights-to-ridaforolimus
The probability to file has moved from 65% to 95% from Harvey's comments.
IR will give you squat...
Exactly my point. The nuance has changed:
DewDiligence, I disagree. In the strictest, technical sense, you are correct. In practical terms, you are incorrect. To think that some of the data mining is not complete and shared with Ariad by Merck at this point is plain silly. Harvey would not stated what he said today, unless he has the confidence that Merck will file..
At least the question of whether Merck is, or is not going to file has been answered..
Actually, I think Merck is now the only potential buyer of Ariad.. No bidding
Harvey is shrewed. There are a huge number of ex pharma sales reps available. One thing.. creating a marketing and sales team takes a whole lot of funds to pull off successfully. Are they going to do another secondary upon approval of Rida??
Well, imho, this should prove to those doubters on this board (you know who you are)that Havey meant what Harvey said, "Ariad plans to be a standalone oncology company". Harvey is a shrewed business man!
You will want to listen to Harvey's presentation from yesterday in Miami. He has refresehed the a few of the slides, but more importantly, he has added additional color and detail to the progress of their pipline.. i.e., they will follow the script for '113 that they did for Pona.. phase 1-2 trial initiated by the middle of this year, and then they will move directly to a registration trial. Expect Merck to file NDA for Rida just after ASCO (as another poster indicated), and mentioned that PFE's ALK inhibitor wasn't originally designed for ALK..
Saudi Police open fire on protesters .. better buckle up with your Ariad shares.
In an amazing stroke of coincidence, the prison cell they are preparing for the accused is the same cell that Martha Stewart occupied. The big difference with the accused's occupation is that it will be for a very, very, very long time..
Looks like the fourth conference was the charm.. Those well heeled Cowan clients..
Yes. Ariad has a breakout session after everyone of these conferences. The good news is whatever they discuss, doesn't seem to influence the stock price, so there is no private information being exchanged that could unfairly move the stock.. The bad news is there is no news that moves the stock.. Think about it..
Just hiding until after the storm, and we come out when we reach ASCO..
Harvey is saying all the right words at all the conferences over the last few days, but no one appears to be ready to jump on the train yet..
BioTechHedge, you may want to RE-READ what I stated in my post!!!
I really like Harvey's comment from yesterday that they will have additional information this year on their plans for NEW indications for ALL THREE of their compounds.. They are REALLY going to fill that pipeline..
I just don't see a way for them to deliver a fourth compound this year (which seems reasonably to me).
Kingfisher7234, you may be misguided.. the value of Ariad is in Pona, not Rida..
$5.86 is the 50 day MA, we fall through that on a close, look out below.. Dr. Berger has three or four presentations in the next 7 days or so.. let's see if that helps..
rkrw, its a reference to your recent post that there are 3 or 4 existing mTOR inhibitors, and you considered that a negative and will squeeze the market cap multiple of these companies.. If you peel the onion, you will see that they are in general for different indications..
rkrw, please keep in mind all the indications that Ariad is persuing are all, unfortunately/fortunately growing markets, due to the aging of the population. Cancer is primarly a disease of the old... I know I'm stating the obvious..
Without question, we will get to the promised land quicker in a buy out. I still think time is on our side, however. (as long as the money holds out). What I mean by that, is each day forward down each of the trials, adds to the final value of each of Ariad's compounds... Pre-lim results of pona at the end of this year adds more value than today's value..
Wow,they did jump on this at the very end of the day..
BTH, are you going to double down?
FWIW indeed!!